| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.72▲ | 2.71▲ | 2.70▲ | 2.75▼ | 2.39▲ |
| MA10 | 2.71▲ | 2.69▲ | 2.69▲ | 2.53▲ | 2.67▲ |
| MA20 | 2.69▲ | 2.69▲ | 2.72▲ | 2.40▲ | 2.54▲ |
| MA50 | 2.68▲ | 2.73▲ | 2.59▲ | 2.73▲ | 2.69▲ |
| MA100 | 2.72▲ | 2.57▲ | 2.42▲ | 2.51▲ | 4.45▼ |
| MA200 | 2.71▲ | 2.41▲ | 2.46▲ | 2.50▲ | 12.32▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.006▲ | 0.005▲ | -0.011▼ | 0.072▲ | 0.008▲ |
| RSI | 68.623▲ | 56.350▲ | 57.177▲ | 59.707▲ | 51.873▲ |
| STOCH | 100.000▲ | 81.481▲ | 53.509 | 76.753 | 14.402▼ |
| WILL %R | 0.000▲ | 0.000▲ | -37.500 | -21.918▲ | -87.121▼ |
| CCI | 108.414▲ | 175.475▲ | 66.712 | 89.326 | -10.294 |
| MA | $VERU Price Crossed Above MA(50) | Set Alert |
|
Sunday, August 09, 2026 11:31 PM
Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – ...
|
|
Tuesday, August 04, 2026 01:30 AM
When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule ...
|
|
Monday, July 27, 2026 05:10 AM
MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/08/26 | 2.695 | 2.73 | 2.66 | 2.73 | 93,703 |
| 13/08/26 | 2.76 | 2.76 | 2.6511 | 2.70 | 182,075 |
| 12/08/26 | 2.78 | 2.80 | 2.71 | 2.74 | 181,363 |
| 11/08/26 | 2.75 | 2.83 | 2.6901 | 2.79 | 454,167 |
| 10/08/26 | 2.375 | 2.89 | 2.33 | 2.77 | 1,593,170 |
| 07/08/26 | 2.36 | 2.39 | 2.3101 | 2.33 | 258,575 |
| 06/08/26 | 2.35 | 2.42 | 2.28 | 2.31 | 234,554 |
| 05/08/26 | 2.39 | 2.39 | 2.30 | 2.33 | 89,565 |
| 04/08/26 | 2.30 | 2.3901 | 2.27 | 2.37 | 255,457 |
| 03/08/26 | 2.32 | 2.32 | 2.21 | 2.26 | 235,772 |
|
|
||||
|
|
||||
|
|